StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.51−0.30 (-1.08%)

Close on Nov 18, 2026Market cap $1.42BP/E –Yield 0.00%

Immunocore operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Immunocore's operating income for the twelve months ending Jun 30, 2026 was -$22.58M. For fiscal 2025 it was -$45.35M. The highest annual figure on record is -$45.35M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.35M–
FY2024Dec 31, 2024-$70.46M–
FY2023Dec 31, 2023-$59.65M–
FY2022Dec 31, 2022-$51.71M–
FY2021Dec 31, 2021-$174.59M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.00M–
Q1 FY2026Mar 31, 2026$7.28M–
Q4 FY2025Dec 31, 2025-$19.69M–
Q3 FY2025Sep 30, 2025-$7.17M–
Q2 FY2025Jun 30, 2025-$14.88M–
Q1 FY2025Mar 31, 2025-$3.62M–
Q4 FY2024Dec 31, 2024-$19.45M–
Q3 FY2024Sep 30, 2024-$8.50M–
Q2 FY2024Jun 30, 2024-$16.02M–
Q1 FY2024Mar 31, 2024-$26.49M–
Q4 FY2023Dec 31, 2023-$17.05M–
Q3 FY2023Sep 30, 2023-$14.14M–
Q2 FY2023Jun 30, 2023-$13.76M–
Q1 FY2023Mar 31, 2023-$14.70M–

More Immunocore figures

See a number that looks wrong?